|
Citation
|
Agustina T, Calle A, Fontela E, Toledo MG, Nadile D, Cassara FP, Thomson A, Acosta P, Thomson A. Neurology 2015; 84(14 Suppl): P3.198. |
|
Abstract
|
BACKGROUND: Depression is a frequent psychiatric comorbidity in patients with epilepsy, carrying a negative impact on their quality of life and an increase in the suicide risk (SR).
OBJECTIVE: To follow up a group of patients that presented SR in the year 2010, evaluated by the MINI scale (Mini International Neuropsychiatric Interview).
MATERIALS AND METHODS: In a consecutive cohort of epileptic patients that in 2010 presented SR according to the MINI scale, we analyzed the evolution of their mood disorder by telephonic interviews. The NDDI-E (Neurological Disorders Depression Inventory for Epilepsy) and MINI scales were administered. We asked about psychiatric, psychological or pharmacological treatments (FxPsicT).
RESULTS: 151 patients were evaluated in 2010, 47(31[percnt]) of which presented SR according to MINI. 59[percnt] low SR, 20.5[percnt] moderate SR, and 20.5[percnt] severe SR. 29 patients were contacted (62[percnt]). None of the contacted subjects committed suicide during our follow up. 17 patients with low SR in 2010: 11(65[percnt]) currently without SR, FxPsicT intervened in 50[percnt]. 6(35[percnt]) persist with low SR under FxPsicT. 6 patients with moderate SR in 2010: 1 persist with moderate SR, 1has low SR under FxPsicT, and 3 without SR under TtoFPsic. The remaining patient worsened (severe SR), treated with olanzapine. 6 patients with severe SR in 2010: 2 without SR, 3 low SR, and 1 persists with severe SR (diagnosed with Bipolar Disorder). Everyone under FxPsicT. The NDDI-E score correlates with the SR (Mean: No Risk 11.17, Low 17.8, Moderate 22, Severe 28.5, p=0.017).
CONCLUSIONS: Depression and SR should be screened for in epileptic patients. It is important to detect patients at risk in order to treat them, since psychological or psychiatric interventions had proven to decrease the suicide risk in our population. We also found that the level of depression scored by NDDI-E correlates with the suicide risk.
Disclosure: Dr. Pagani Cassara has nothing to disclose. Dr. Calle has received personal compensation for activities with UCB Pharma as a scientific advisory board member. Dr. Fontela has nothing to disclose. Dr. Gonzalez Toledo has nothing to disclose. Dr. Nadile has nothing to disclose. Dr. Pagani Cassara has nothing to disclose. Dr. Thomson has nothing to disclose. Dr. Acosta has nothing to disclose. Dr. Thomson has nothing to disclose.
Language: en |